- BNF:
- 8.2.4
- Status:
- Red
- Decision Date:
- None
Comments
RED1,2,3,4,8: NICE TA527 - Beta interferons (beta-1a (Avonex & Rebif) & beta-1b (Extavia)) and glatiramer acetate for treating multiple sclerosis (decision date - July 2018)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 4: Specifically designated as “hospital only” by product licence or by DH/NICE
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again